Seagen Inc. (NASDAQ:SGEN – Get Rating) CEO Clay B. Siegall sold 17,043 shares of the company’s stock in a transaction dated Thursday, May 12th. The shares were sold at an average price of $125.69, for a total transaction of $2,142,134.67. Following the transaction, the chief executive officer now owns 666,060 shares in the company, valued at approximately $83,717,081.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
NASDAQ:SGEN opened at $135.63 on Friday. Seagen Inc. has a 52 week low of $105.43 and a 52 week high of $192.79. The firm has a 50-day moving average price of $138.95 and a two-hundred day moving average price of $146.14.
Seagen (NASDAQ:SGEN – Get Rating) last posted its quarterly earnings data on Thursday, April 28th. The biotechnology company reported ($0.74) EPS for the quarter, beating the consensus estimate of ($0.98) by $0.24. The firm had revenue of $426.50 million during the quarter, compared to analyst estimates of $401.75 million. Seagen had a negative net margin of 41.32% and a negative return on equity of 21.86%. The company’s revenue for the quarter was up 28.5% on a year-over-year basis. During the same quarter last year, the business posted ($0.67) EPS. Equities analysts forecast that Seagen Inc. will post -3.51 earnings per share for the current year.
Several equities analysts have recently weighed in on SGEN shares. Needham & Company LLC dropped their price objective on shares of Seagen from $254.00 to $200.00 and set a “buy” rating on the stock in a report on Monday, February 7th. StockNews.com began coverage on shares of Seagen in a report on Thursday, March 31st. They issued a “hold” rating on the stock. JMP Securities restated a “buy” rating and issued a $157.00 target price on shares of Seagen in a report on Monday, April 18th. Royal Bank of Canada lowered their target price on shares of Seagen from $154.00 to $132.00 and set a “sector perform” rating on the stock in a report on Thursday, February 10th. Finally, Stifel Nicolaus lowered their target price on shares of Seagen from $180.00 to $145.00 in a report on Thursday, February 10th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and seven have issued a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Buy” and an average price target of $161.62.
About Seagen (Get Rating)
Seagen Inc, a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer.
- Get a free copy of the StockNews.com research report on Seagen (SGEN)
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
Receive News & Ratings for Seagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seagen and related companies with MarketBeat.com's FREE daily email newsletter.